Direct-to-consumer occupational health monitoring: opportunities, concerns, ethical considerations
Year: 2025
Type: article
Abstract: The framework established by health and safety legislation in occupational health has proven to be an effective mechanism for delivering high-quality services to workers. However, occupational medicine faces challenges due to a significant shortage of medical professionals, resulting in possibly inadequate care and follow-up for workers. Additionally, regulations restrict the ability of occupational health and safety (OSH) providers to innovate their services, making it difficult to keep up with rising consumer expectations. This changing market context has resulted in the emergence of new market entrants offering direct-to-consumer (DTC) OSH solutions. DTC testing allows individuals to access a wide array of medical, laboratory and even genetic tests without the need for an OSH provider’s involvement. As Wilson and Jungner highlighted in their foundational work on screening principles (1968), screening organizations are adapting to this evolving landscape, where technological advances often outpace the evidence base supporting screening practices [1]. Characterized by the use of advanced technologies to deliver accessible and convenient services, they often circumvent traditional regulatory frameworks. While these developments introduce flexibility and accessibility, they also raise critical concerns regarding the quality and reliability of their services. The market players offering DTC monitoring services demonstrate diversity in their offerings. At one end of the spectrum are fully standalone services, where users navigate all stages of the process independently, while at the other are fully supported services, providing professional guidance at every step: test-taking, analysis, intervention planning and follow-up. Between these extremes lie hybrid models, such as self-tests with varying levels of professional involvement, laboratory-supported analysis and automated AI-driven interpretations (Table 1). Monitoring process phases and categories of human guidance in testing Monitoring process phases and categories of human guidance in testing It is important to note that there is not only variety in the guidance these services offer, or the phases in which it does so, but also in the samples that are tested, as well as the different markers. It is evident that traditional and regulated occupational health providers are challenged by this large variety of DTC services, with many unbundling the testing process and specializing in niche areas. We refer to this threat as the ‘death by a thousand cuts’ scenario, where the cumulative impact of numerous players taking away smaller and larger chunks of the entire OSH approach poses a substantial risk to regulated incumbents. The erosion of traditional OSH providers may be sped up and intensified by the different nature of incumbent and challenger. Traditional occupational health providers must adhere to strict regulations that have been historically established in a well-known market context. In contrast, DTC players operate in a less regulated space, allowing them to be more agile and responsive. It is in effect an unfair fight with both parties adhering to a different set of rules. As employers struggle to attract top talent, offering health benefits and effective health management has become a key differentiating factor, further amplifying the DTC challengers’ market presence and influence. To understand and evaluate the role of DTC players within the broader OSH landscape, one needs to consider both the benefits and drawbacks of DTC medicine. A major concern is the risk of self-diagnosis and incorrect use of tests. Several studies emphasize the importance of physician involvement in result interpretation and counselling [1]. Without guidance from OSH providers, consumers may misinterpret symptoms or misunderstand instructions in the test-taking process, leading to ‘worried well persons’ taking of inappropriate actions, iatrogenesis and adverse health outcomes. Moreover, certain tests may have potential interactions with existing health problems or other tests, highlighting the importance of medical supervision during the test-taking. Furthermore, the lack of personal contact with health experts in DTC medicine raises questions about the quality of care and patient safety [2]. While online consultations and telemedicine platforms can provide some level of support, they cannot completely replace the comprehensive assessment provided in traditional OSH settings. The rise of DTC testing also has implications for the doctor–patient relationship [3]. As patients become more autonomous, the necessity to consult or inform their doctor before taking such tests may diminish. This phenomenon complicates having an overall view of the patient’s health. Furthermore, the increasing autonomy of patients may result in the overutilization of healthcare services, potentially leading to unnecessary treatments, and consequently, rising healthcare costs. This could strain public healthcare systems and insurance models, impacting overall societal costs [4]. Another pressing concern is the variability in the quality and reliability of the tests [5]. Consumers have access to a wide variety of tests, one being more scientifically accurate than the other. Consumers may struggle to discern clinically validated tests from others. Moreover, the regulatory landscape for DTC testing is currently a patchwork of policies that vary by region and jurisdiction. As these tests are available internationally through online purchase, consumers are unknowingly exposed to tests that might not be allowed in their region [6]. Lastly, the ethical implications of DTC testing should be mentioned [7]. Private market players might not adhere to the strict regulations concerning privacy and the processing of data, putting consumers at risk as they often share sensitive health information with private companies. Apart from the potential risks and challenges discussed above, innovation also brings opportunities with it. One of the main benefits of DTC medicine is increased accessibility [8]. Second, DTC medicine has increased the awareness and public interest in the prevention of health issues. These platforms stimulate staying or becoming healthy, often providing comprehensive information about health services, and allowing patients to make informed decisions about their health and monitor their progress [9]. Moreover, DTC medicine can potentially reduce the direct costs of specific healthcare services by streamlining the supply chain [10]. OSH providers can offer services at lower prices and address the issue of the declining number of occupational health experts. Additionally, the flexibility of DTC platforms, compared to the more regulated pricing of traditional providers, could lead to more tailored and potentially cost-effective OSH solutions. Finally, the players offering DTC testing have an undeniable focus on convenience. The ability to order a test online, perform it at home, and receive results directly, including a follow-up plan in a state-of-the-art digital environment, as well as the possibility to perform follow-up tests bypasses many of the barriers associated with traditional healthcare. Having health information on your personal device, often integrating data from other sources such as health wearables, improves the patient experience drastically and makes it personalized [10]. As new technologies such as generative AI are even more integrated, new insights are unlocked and interpretation of complex medical tests is automated further. Taking into account the opportunities and threats DTC medicine offers to the traditional approach of occupational medicine, a hybrid approach emerges. Unlike DTC medicine, provider-to-consumer (PTC) medicine involves the direct delivery of health services to consumers within a clinical setting by health professionals. This model combines the accessibility and convenience of direct access to health services with the expertise and supervision of trained professionals. By integrating the provision of health services into routine practice, PTC medicine ensures that patients receive appropriate tests tailored to their individual needs, while also facilitating ongoing monitoring and follow-up care. Private–public partnerships (PPPs) can play a crucial role in promoting the implementation of PTC medicine. Collaboration between health service providers, technology companies and government agencies can pool resources, expertise and infrastructure to develop and scale up PTC initiatives. Each stakeholder can concentrate their efforts and resources on their areas of expertise, leading to a higher combined value through integration. For example, technology companies can develop digital platforms to provide health services, while government agencies can provide regulatory frameworks and funding mechanisms to ensure the quality and accessibility of health services. Moreover, the scale of PPPs can be used to invest in technological solutions to improve the delivery of PTC services, such as digital apps for requesting tests, laboratory analysis and promoting health education. These innovations can improve efficiency, communication and coordination among stakeholders, ultimately improving the quality and accessibility of healthcare services. Traditional occupational healthcare systems must adapt to the presence of DTC testing, developing protocols for how these tests could be integrated into patient care to reap its benefits all the while ensuring the quality of care and an integrated approach that enables healthcare providers to interpret and act upon DTC test results. Instead of existing independently, DTC testing should be integrated into the regulated OSH framework in order to enhance well-being in the workplace.
Source: Occupational Medicine
Authors: Lode Godderis, Charles Decree, Tuur Devooght
Institution: KU Leuven
Language: English
Subfield: Occupational Therapy
Field: Health Professions
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,925
OpenAlex ID: W4408142067